Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

Inclusion Criteria:

- Part I: Histologically confirmed advanced/metastatic solid tumor (except prostate
cancer and squamous non-small cell lung cancer [NSCLC])

- Part II: Histologically confirmed advanced/metastatic platinum-resistant ovarian
carcinoma (aPROC), head and neck squamous cell carcinoma (HNSCC), or non-squamous
NSCLC previously treated with anti-PD-L1/PD-1 inhibitor alone or in combination (e.g.
atezolizumab, nivolumab, pembrolizumab, durvalumab, avelumab)

- Checkpoint inhibitor (CPI)- experienced patients must have experienced documented
disease progression on or after PD-L1/PD-1 inhibitor therapy

- In CPI-experienced patients, the PD-L1/PD-1 inhibitor must have been part of the most
recent systemic anticancer therapy administered prior to study enrollment

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

- Life expectancy >/= 16 weeks

- Adequate hematologic, renal, hepatic, and cardiovascular function

- Measurable disease per Response Evaluation Criteria in Solid Tumors, v 1.1 (RECIST
v1.1)

- Tumors must be acceptable for biopsy

- Agreement to use adequate contraceptive measures among men or among women of
childbearing potential

Exclusion Criteria:

- Prostate cancer or squamous NSCLC

- Recent systemic anti-cancer treatment

- Prior treatment with anti-programmed death (PD) 1 or anti-programmed death ligand
(PD-L) 1 therapeutic antibody, vanucizumab, or compounds targeting cluster of
differentiation (CD) 40

- Part II: Treatment targeting vascular endothelial growth factor (VEGF) or receptor
within 12 months prior to enrollment

- Systemic immunosuppressive medication within 2 weeks prior to day 1 of cycle 1

- Chronic daily treatment with non-steroidal anti-inflammatory drugs

- Unacceptable/unresolved toxicity from prior anti-cancer therapy

- Patients who have had a surgical procedure or significant traumatic injury within 28
days prior to initiation of study treatment, or a core biopsy or other minor surgical
procedure within 7 days prior to initiation of study treatment

- Bisphosphonate therapy for symptomatic hypercalcemia

- Significant vascular disease

- History of hypertensive crisis or hypertensive encephalopathy

- Current or recent use of aspirin (>325 mg/day) or clopidogrel (>75 mg/day)

- History of vein thrombosis/thromboembolism, or use of anticoagulants within 7 days
prior to study drug

- Primary tumor in place in participants with colorectal cancer, or evidence of bowel
involvement (metastasis, direct tumor invasion) in participants with other
non-gastrointestinal cancer

- Significant cardiovascular or cerebrovascular disease within 6 months prior to D1 of
C1

- History of bowel obstruction, perforation, or abscess

- Prior radiotherapy to pelvis or abdomen, recto-sigmoid involvement, or bowel
involvement among participants with aPROC

- Severe non-healing wound, active ulcer or untreated bone fracture

- Pregnant or lactating women

- History of autoimmune disease

- Human immunodeficiency virus (HIV) or hepatitis B or C

- Severe infection or receipt of a live/attenuated vaccine within 4 weeks prior to D1 of
C1

- Other significant malignancies within 3 years prior to D1 of C1

- Allergy/hypersensitivity to study drug

- Prior allogeneic bone marrow or solid organ transplant

- Other conditions/findings that may contraindicate use of study drug

- Major surgery within 4 weeks prior to study drug

- Known clinically significant liver disease

- History of hemoptysis or bleeding diathesis, or known coagulopathies

- Known symptomatic or untreated central nervous system (CNS) malignancy